NeuroBo Pharmaceuticals, Inc. (NRBO)
NASDAQ: NRBO · Real-Time Price · USD
2.400
-0.050 (-2.04%)
At close: Nov 20, 2024, 4:00 PM
2.250
-0.150 (-6.25%)
After-hours: Nov 20, 2024, 7:51 PM EST
NeuroBo Pharmaceuticals Employees
NeuroBo Pharmaceuticals had 8 employees as of December 31, 2023. The number of employees increased by 6 or 300.00% compared to the previous year.
Employees
8
Change (1Y)
6
Growth (1Y)
300.00%
Revenue / Employee
n/a
Profits / Employee
-$3,466,625
Market Cap
20.68M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | 6 | 300.00% |
Dec 31, 2022 | 2 | -3 | -60.00% |
Dec 31, 2021 | 5 | -2 | -28.57% |
Dec 31, 2020 | 7 | -5 | -41.67% |
Dec 31, 2019 | 12 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Enlivex Therapeutics | 71 |
Pieris Pharmaceuticals | 50 |
VSee Health | 40 |
GlycoMimetics | 35 |
Pulmatrix | 22 |
BriaCell Therapeutics | 16 |
Cocrystal Pharma | 12 |
MIRA Pharmaceuticals | 3 |
NRBO News
- 3 days ago - NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases - PRNewsWire
- 8 days ago - NeuroBo Pharmaceuticals to Participate in Investor Conferences in November - PRNewsWire
- 14 days ago - NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 17 days ago - NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH - PRNewsWire
- 7 weeks ago - NeuroBo Pharmaceuticals to Participate in Investor Conferences in October - PRNewsWire
- 7 weeks ago - NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity - PRNewsWire
- 2 months ago - NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - PRNewsWire
- 3 months ago - NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire